



PRODUCT: **XOSPATA®**

COMPANY: Astellas Pharma Inc.

THERAPEUTIC AREA & INDICATION:

Tyrosine kinase inhibitor for adults with relapsed or refractory acute myeloid leukemia (AML) with the tyrosine kinase-3 gene mutation

ABOUT THE PRODUCT

Gilteritinib was discovered through a research collaboration with Kotobuki Pharmaceutical Co., Ltd., and Astellas has exclusive global rights to develop, manufacture and commercialize gilteritinib. XOSPATA® is approved in the U.S., Japan, Europe, Canada, Korea, Brazil and Australia for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with an FMS-like tyrosine kinase 3 (FLT3) mutation, and is currently undergoing regulatory review in China.

Gilteritinib has demonstrated inhibitory activity against FLT3-ITD, a type of FLT3mut+ that is seen in approximately one-third of patients with AML, as well as FLT3-TKD mutation.